Budesonide CRL Another Setback For Takeda’s ‘Wave 1’ Pipeline

Setback for company's near-term launch goals and US patients with rare esophageal inflammatory condition as regulator asks for additional clinical data. 

esophagitis
US FDA Decides Not To Approve First Drug For Eosinophilic Esophagitis • Source: Alamy

Takeda Pharmaceutical Co. Ltd. has received a Complete Response Letter (CRL) from the US Food and Drug Administration for its 2020 new drug application for Eohilia (TAK-721), an oral suspension of the corticosteroid budesonide for eosinophilic esophagitis (EoE).

The decision marks another setback for one of the most advanced products in the major Japanese firm’s “Wave 1” pipeline...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip